BALTIMORE, Sept. 20 /PRNewswire/ — CSA Medical, Inc. announced
today that New York University Langone Medical Center (NYU) has
begun providing Spray Cryotherapy treatment for patients. Dr.
Costas (Gus) Bizekis, Assistant Professor of Medicine, in the
department of Cardiothoracic Surgery is performing this procedure.
Dr. Bizekis is the Director of Esophageal Surgery in the Department
of Cardiothoracic Surgery at NYU Langone Medical Center. Dr.
Bizekis has extensive experience in all aspects of esophageal
disease management.
“Spray Cryotherapy is an exciting addition to the tools offered
at NYU as it is a minimally invasive (endoscopic) approach that is
very patient friendly,” says Dr. Bizekis. “We freeze and kill the
unwanted tissue with very little pain and patients can generally
return to work the next day. Some patients are not candidates for
surgery or they have failed to respond to other treatments like
chemotherapy and radiation and spray cryotherapy gives us another
option. Recently published data also demonstrates it to be safe and
effective as a first-line or primary therapy.”
Spray cryotherapy utilizes ultra-cold (-196 degrees C) liquid
nitrogen delivered in a low pressure spray to freeze and destroy
unwanted tissue in the body.
“We are thrilled to have NYU as our 75th customer. It is fitting
that such a world-class, patient centered, integrated academic
medical center would mark a landmark event for the company” said
Ric Hughen, Vice President-Sales & Marketing. “NYU joins a
group of preeminent medical centers on the leading edge of new
technology adoption for the benefit of their patients”.
CSA Medical, Inc. develops and manufactures a proprietary
therapeutic interventional platform, the CryoSpray Ablation™
System. The CSA System utilizes a patented spray cryogenic
technology that allows a physician to freeze and destroy a wide
range of unwanted tissues via an endoscope.
For more information, pl
‘/>”/>
